Bone Biologics

Bone Biologics EBITDA per Share

The EBITDA per Share of Bone Biologics (BBLG) as of Oct 27, 2026 is -2.75 USD. In the previous year, EBITDA per Share was -1.43 USD — a change of 92.78% (lower).

EBITDA per Share

-2.75USD

YoY

92.78%

Last updated:

EBITDA per Share of Bone Biologics is 2025 -2.75 USD. EBITDA per Share of Bone Biologics was 2024 -1.43 USD. It decreases by 92.78% lower compared to the previous year.

The Bone Biologics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-382.34 USD
Jan 1, 2019
-47.89 USD
Jan 1, 2020
-0.03 USD
Jan 1, 2021
-25.56 USD
Jan 1, 2022
-57.45 USD
Jan 1, 2023
-20.54 USD
Jan 1, 2024
-1.43 USD
Jan 1, 2025
-2.75 USD
The Bone Biologics EBITDA per Share history
YEAREBITDA per ShareYoY
-2.75USD+92.78%
-1.43USD-93.05%
-20.54USD-64.25%
-57.45USD+124.79%
-25.56USD+94,944.85%
-0.03USD-99.94%
-47.89USD-87.47%
-382.34USD+56,052.86%
-0.68USD-99.98%
-2,746.79USD+882.30%
-279.63USD+118,730.81%
-0.24USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bone Biologics Stock analysis

What does Bone Biologics do? Bone Biologics Corp. generates revenue through the development and sale of its NELL-1/DBM Fusion Device, a bone regeneration product for spinal fusion procedures. The device combines NELL-1, a recombinant human protein, with demineralized bone matrix (DBM) to provide targeted bone regeneration control. Medical professionals use the product for spine implants, non-union trauma cases, and osteoporosis treatments. The company's platform technology, centered on NELL-1, is developed through laboratory and animal research to support applications in bone void filling and skeletal regeneration. The firm focuses on osteopromotive applications using NELL-1, a skeletal-specific growth factor proven in laboratory models to replicate human growth and development. NELL-1 is marketed as a bone void filler and is integrated into spinal fusion devices. The company's revenue streams derive from the commercialization of NELL-1-based products targeting orthopedic and spinal surgery markets. Medical device companies and healthcare providers purchase the NELL-1/DBM Fusion Device for clinical use in bone regeneration procedures. Bone Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bone Biologics stock

EBITDA per Share of Bone Biologics is -2.75 USD in 2025.

EBITDA per Share of Bone Biologics changed from -1.43 USD to -2.75 USD, representing a 92.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Bone Biologics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bone Biologics

All Key Metrics — Bone Biologics